NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Dec. 10, 2015--
Lantheus
Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus
Medical Imaging, Inc. (“LMI”), a global leader in developing,
manufacturing, selling and distributing innovative diagnostic imaging
agents and products, today announced the appointment of Jack Crowley as
interim Chief Financial Officer, effective December 10, 2015. Mr.
Crowley replaces John Bakewell, who has served as Chief Financial
Officer since June 2014 and has resigned from the Company to accept
another position.
Mr. Crowley, age 51, brings to the role more than 28 years of financial
management and accounting experience. Since joining the Company in
September 2010 as Director of Accounting, Mr. Crowley has steadily
advanced to assume broader executive leadership roles. He was promoted
to Vice President of Finance in April 2013 and to Chief Accounting
Officer in March 2015. Mr. Crowley will report directly to Mary Anne
Heino, President and Chief Executive Officer.
“I have had the pleasure of working with Jack for several years and have
been impressed with his management of the Finance function,” said Ms.
Heino. “Jack has consistently been a strong leader who has shown
tremendous professional growth, and I am pleased that he will be taking
on this role.”
“Jack is a highly skilled financial professional with deep knowledge of
our business and industry,” said Sam Leno, Chairman of the Audit
Committee of the Board. “I look forward to working with Jack as he takes
on this new role.”
Mr. Crowley joined the Company from Biogen Idec where he served in the
roles of Director of Finance and Assistant Corporate Controller and
Director of External Reporting. Previously, Mr. Crowley was the Director
of Accounting at Fisher Scientific International. Earlier in his career,
he worked in serval public accounting firms, including as a Senior
Manager in the Audit practice of PriceWaterhouseCoopers.
Mr. Crowley holds a Master of Business Administration from the
University of Massachusetts and a Bachelor of Science in Business
Administration from Westfield State University.
About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.
Lantheus
Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc.,
which is a global leader in developing, manufacturing, selling and
distributing innovative diagnostic imaging agents and products. LMI
provides a broad portfolio of products, which are primarily used for the
diagnosis of cardiovascular diseases. LMI’s key products include the
echocardiography contrast agent DEFINITY® Vial for
(Perflutren Lipid Microsphere) Injectable Suspension; TechneLite®
(Technetium Tc99m Generator), a technetium-based generator that provides
the essential medical isotope used in nuclear medicine procedures; and
Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent
used to evaluate pulmonary function and for imaging the lungs. LMI is
headquartered in North Billerica, Massachusetts, and has offices in
Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151210006458/en/
Source: Lantheus Holdings, Inc.
Lantheus Holdings, Inc.
Meara Murphy, 978-671-8508
